Understanding Cushing Disease: Validation & Orientation
At a Glance
Cushing disease is a rare, highly treatable condition caused by a pituitary tumor (PitNET) that triggers excess cortisol production. While diagnosis is often delayed because symptoms mimic common health issues, specialized surgery and modern medications offer a clear path to remission.
If you have been searching for answers for months or even years, feeling like your body has become a stranger to you, you are not alone. The journey to a Cushing disease diagnosis is often described by patients and doctors alike as a “diagnostic odyssey” [1]. Because its symptoms—like weight gain, high blood pressure, and anxiety—mimic many common conditions, it is frequently overlooked in its early stages [2].
Reaching this point is a significant milestone. You are no longer “searching”; you are now moving toward a solution.
Three Stabilizing Facts
When you are in the “panic spiral” of a new diagnosis, it helps to anchor yourself in these three clinical realities:
- It is highly treatable: There is a clear, international standard of care (a medical guideline that doctors follow) for this condition, starting with specialized surgery that can lead to a definitive cure [3][4].
- You have a path to remission: While the road may be long, most patients achieve biochemical remission (normal hormone levels) through surgery or a combination of medical therapies [5][6].
- Modern medicine is evolving: If first-line treatments are not enough, new medications (such as osilodrostat) have shown high effectiveness in controlling hormone levels for the vast majority of patients [7].
Validating the “Diagnostic Odyssey”
It is common for patients to wait an average of 2 years from the time their symptoms first appear to the moment they receive a formal diagnosis [8][9]. During this time, many patients experience “medical gaslighting,” where their symptoms are dismissed as lifestyle choices or primary psychiatric issues [1].
The prolonged exposure to high cortisol (the body’s primary stress hormone) can cause neuropsychiatric disorders, including anxiety, depression, and “brain fog” [10]. Understanding that these feelings have a physical, hormonal cause can be a vital step in your emotional recovery [11].
Defining Cushing Disease vs. Cushing Syndrome
While these terms are often used interchangeably, they mean different things in a clinical setting:
- Cushing Syndrome: This is the broad “umbrella term” for any condition where the body has too much cortisol over a long period [12].
- Cushing Disease: This is a specific type of Cushing Syndrome. It occurs when a small tumor in the pituitary gland (located at the base of the brain) produces too much ACTH, the hormone that tells your adrenal glands to make cortisol [13].
Medical professionals have recently updated the terminology for these pituitary tumors. They are now officially called Pituitary Neuroendocrine Tumors or PitNETs [14]. This name change reflects that these are not just simple “growths” (adenomas) but active tumors that interact with your body’s endocrine system [15].
Understanding the Rarity
Cushing disease is a rare condition, with only about 1.6 cases diagnosed per million people each year [16]. Because it is so rare, your primary care doctor or a local general endocrinologist may only see one or two cases in their entire career. This is why it is essential to seek care at a Pituitary Center of Excellence, where specialists see hundreds of “rare” cases like yours and have the expertise required for complex pituitary surgery [17].
What to Expect Next
Your journey is shifting from a search for “why” to a plan for “how.” The primary treatment is usually transsphenoidal surgery (TSS), where a surgeon reaches the tumor through the nose [3]. If surgery is not the right fit or does not result in a full cure, your team may use medications like somatostatin receptor ligands or dopamine agonists to manage your hormone levels [18].
While the “legacy” of high cortisol (such as changes in bone density or mood) can take time to heal, the first step is stopping the source [6][11]. You are now on that path.
Common questions in this guide
What is the difference between Cushing disease and Cushing syndrome?
Is Cushing disease curable?
What happens if surgery does not cure my Cushing disease?
Why does it take so long to get a Cushing disease diagnosis?
What does the term PitNET mean?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is your experience in managing pituitary neuroendocrine tumors (PitNETs) specifically?
- 2.Is my case being reviewed by a multidisciplinary team, including a neurosurgeon and a neuroendocrinologist?
- 3.Based on my imaging and labs, is my tumor classified as a microadenoma or a macroadenoma, and how does this impact my success rate for surgery?
- 4.How do you define 'biochemical remission' versus 'symptomatic recovery' in your practice?
- 5.If surgery is not immediately successful, what is the 'Plan B' for medical management or radiation?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (18)
- 1
Unmet needs in Cushing's syndrome: the patients' perspective.
Valassi E, Chiodini I, Feelders RA, et al.
Endocrine connections 2022; (11(7)).
PMID: 35904235 - 2
A commentary on Diagnosing Cushing's disease in the context of renal failure.
Raff H, Cohen EP, Findling JW
European journal of endocrinology 2019; (181(4)):C9-C11.
PMID: 31349218 - 3
Cushing's disease.
Ferriere A, Tabarin A
Presse medicale (Paris, France : 1983) 2021; (50(4)):104091 doi:10.1016/j.lpm.2021.104091.
PMID: 34718112 - 4
Pituitary surgery in Cushing's disease: first line treatment and role of reoperation.
Jones PS, Swearingen B
Pituitary 2022; (25(5)):713-717 doi:10.1007/s11102-022-01254-8.
PMID: 35857269 - 5
Outcomes of endoscopic transsphenoidal surgery for Cushing's disease.
Brady Z, Garrahy A, Carthy C, et al.
BMC endocrine disorders 2021; (21(1)):36 doi:10.1186/s12902-021-00679-9.
PMID: 33658018 - 6
Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.
Pivonello R, Fleseriu M, Newell-Price J, et al.
Journal of endocrinological investigation 2024; (47(10)):2437-2448 doi:10.1007/s40618-024-02359-6.
PMID: 38696122 - 7
Suprasellar Tension Pneumatocele after Endoscopic Transsphenoidal Surgery for Pituitary Macroadenoma.
Sharma AK, Mehta R, Chandrakar N, et al.
Asian journal of neurosurgery 2020; (15(3)):763-765 doi:10.4103/ajns.AJNS_253_19.
PMID: 33145250 - 8
Clinical presentation and etiology of Cushing's syndrome: Data from ERCUSYN.
Valassi E
Journal of neuroendocrinology 2022; (34(8)):e13114 doi:10.1111/jne.13114.
PMID: 35979717 - 9
Salient Observations from Clinical Profile and Long-Term Outcome of a Cohort of Patients with Ectopic Cushing's Syndrome.
Arjunan D, Jain N, Shah R, et al.
Indian journal of endocrinology and metabolism 2025; (29(4)):434-439 doi:10.4103/ijem.ijem_96_25.
PMID: 40917326 - 10
Improvement in cognitive impairment following the successful treatment of endogenous Cushing's syndrome-a case report and literature review.
Brzozowska MM, Kepreotis S, Tsang F, Fuentes-Patarroyo SX
BMC endocrine disorders 2019; (19(1)):68 doi:10.1186/s12902-019-0401-4.
PMID: 31253144 - 11
The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study.
Ebbehoj A, Søndergaard E, Jepsen P, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(7)):e2921-e2929 doi:10.1210/clinem/dgac174.
PMID: 35311897 - 12
Cushing syndrome: Old and new genes.
Tatsi C, Flippo C, Stratakis CA
Best practice & research. Clinical endocrinology & metabolism 2020; (34(2)):101418 doi:10.1016/j.beem.2020.101418.
PMID: 32414619 - 13
Cushing Disease: Medical and Surgical Considerations.
Bray DP, Rindler RS, Dawoud RA, et al.
Otolaryngologic clinics of North America 2022; (55(2)):315-329 doi:10.1016/j.otc.2021.12.006.
PMID: 35256173 - 14
Pituitary Neuroendocrine Tumor or Pituitary Adenoma? Let's Ask the Epigenome!
Dottermusch M
Endocrine pathology 2025; (36(1)):35 doi:10.1007/s12022-025-09879-8.
PMID: 41060331 - 15
A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS, Ho RS, Ho G, et al.
Frontiers in endocrinology 2024; (15()):1368944 doi:10.3389/fendo.2024.1368944.
PMID: 38756997 - 16
The incidence of Cushing's disease: a nationwide Swedish study.
Ragnarsson O, Olsson DS, Chantzichristos D, et al.
Pituitary 2019; (22(2)):179-186 doi:10.1007/s11102-019-00951-1.
PMID: 30799512 - 17
Update in the Management of ACTH-Secreting Gastroenteropancreatic and Thoracic Neuroendocrine Neoplasms.
Tsoli M, Bel-Ange A, Atlan K, et al.
Current treatment options in oncology 2025; (26(11)):1010-1022 doi:10.1007/s11864-025-01354-0.
PMID: 41042443 - 18
Medical treatment of functional pituitary adenomas, trials and tribulations.
Capatina C, Hanzu FA, Hinojosa-Amaya JM, Fleseriu M
Journal of neuro-oncology 2024; (168(2)):197-213 doi:10.1007/s11060-024-04670-x.
PMID: 38760632
This orientation guide to Cushing disease is for educational purposes only and does not replace professional medical advice. Always consult with a neuroendocrinologist or your specialized care team regarding your diagnosis and personalized treatment plan.
Get notified when new evidence is published on Cushing disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.